EFFICACY AND SAFETY OF TENOFOVIR ALAFENAMIDE ( TAF) AT 2 YEARS IN CHILDREN AND ADOLESCENTS WITH CHRONIC HEPATITIS B ( CHB)

被引：0

作者：

Schwarz, Kathleen B. ^{[1
]}

Bezerra, Jorge A. ^{[2
]}

Choe, Byung Ho ^{[3
,4
]}

Lin, Chuan-Hao ^{[5
]}

Abramov, Frida ^{[6
]}

Wang, Hongyuan ^{[6
]}

Liu, Yang ^{[6
]}

Flaherty, John F. ^{[6
]}

Pacurar, Daniela ^{[7
]}

Kim, Kyung Mo ^{[8
]}

Khaertynova, Ilsiyar ^{[9
]}

Shalimar ^{[10
]}

Wu, Jia-Feng ^{[11
]}

Tandon, Manish ^{[12
]}

Rosenthal, Philip ^{[13
]}

Morozov, Viacheslav ^{[14
]}

Sokal, Etienne M. ^{[15
]}

Chang, Mei Hwei ^{[16
,17
]}

机构：

[1] Univ Calif San Diego, Rady Childrens Hosp San Diego, San Diego, CA 92103 USA

[2] Univ Texas Southwestern Med Ctr, Dallas, TX USA

[3] Kyungpook Natl Univ, Sch Med, Daegu, South Korea

[4] Kyungpook Natl Univ Childrens Hosp, Daegu, South Korea

[5] Childrens Hosp Los Angeles, Los Angeles, CA USA

[6] Gilead Sci Inc, Foster City, CA USA

[7] Carol Davila Univ Med & Pharm, Bucharest, Romania

[8] Univ Ulsan, Asan Med Ctr, Childrens Hosp, Seoul, South Korea

[9] Kazan State Med Univ, Kazan, Russia

[10] All India Inst Med Sci, Delhi, India

[11] Natl Taiwan Univ Hosp, Taipei, Taiwan

[12] MV Hosp & Res Ctr, Lucknow, Uttar Pradesh, India

[13] Univ Calif San Francisco, San Francisco, CA 94143 USA

[14] Hepatolog Med Co, Samara, Russia

[15] Clin Univ St Luc, Brussels, Belgium

[16] Natl Taiwan Univ, Taipei, Taiwan

[17] Children Hosp, Taipei, Taiwan

来源：

HEPATOLOGY | 2023年 / 78卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

1414C

引用

页码：S515 / S517

页数：3

共 50 条

[21] Safety and efficacy of switching to tenofovir alafenamide (TAF) in virally suppressed chronic hepatitis B (CHB) patients with hepatic impairment: week 48 results from a phase 2 open label study
Lim, Young-Suk
Lin, Chun-Yen
Heo, Jeong
Bae, Ho
Chuang, Wan-Long
Hui, Aric Josun
Elkhashab, Magdy
Trinh, Huy
Tan, Susanna
Mo, Shuyuan
Flaherty, John F.
Suri, Vithika
Gaggar, Anuj
Subramanian, Mani
Tsang, Tak Yin Owen
Ryder, Stephen
Andreone, Pietro
Janssen, Harry
JOURNAL OF HEPATOLOGY, 2020, 73 : S872 - S872
[22] EFFICACY AND SAFETY OF TENOFOVIR ALAFENAMIDE IN THE TREATMENT OF DECOMPENSATED CIRRHOTIC PATIENTS WITH CHRONIC HEPATITIS B
Deng, You
Zhang, Shuqian
Chen, Wenya
Li, Jiashuo
Li, Mengqi
Wang, Qi
Zhao, Hong
Qiao, Bing
Xie, Wen
HEPATOLOGY, 2023, 78 : S517 - S518
[23] Investigation of Efficacy and Safety in Chronic Hepatitis B Patients Receiving Tenofovir Alafenamide Treatment
Kahveci, Huseyin Nadir
Yildiz, Orhan
Karabulut, Kaan
Ture, Zeynep
Unuvar, Gamze Kalin
Aygen, Bilgehan
JOURNAL OF CLINICAL PRACTICE AND RESEARCH, 2024, 46 (04):
[24] SAFETY AND EFFICACY OF SWITCHING TO TENOFOVIR ALAFENAMIDE (TAF) IN VIRALLY SUPPRESSED CHRONIC HEPATITIS B (CHB) PATIENTS WITH HEPATIC IMPAIRMENT: WEEK 24 RESULTS FROM A PHASE 2 OPEN-LABEL STUDY
Coffin, Carla
Lim, Young-Suk
Bae, Ho
Heo, Jeong
Hui, Aric J.
Chen, Chien-Hung
Flaherty, John F.
Gaggar, Anuj
Mo, Shuyuan
Hahambis, Thomas A.
Jump, Belinda
Trinh, Huy N.
Tsang, Owen
Janssen, Harry L.
GASTROENTEROLOGY, 2020, 158 (06) : S1320 - S1321
[25] SAFETY AND EFFICACY OF SWITCHING TO TENOFOVIR ALAFENAMIDE (TAF) IN VIRALLY SUPPRESSED CHRONIC HEPATITIS B (CHB) PATIENTS WITH HEPATIC IMPAIRMENT: WEEK 24 RESULTS FROM A PHASE 2 OPEN-LABEL STUDY
Lim, Young-Suk
Lampertico, Pietro
Bae, Ho S.
Chuang, Wan Long
Heo, Jeong
Huang, Yi-Hsiang
Hui, Aric Josun
Lin, Chun-Yen
Fournier, Claire
Flaherty, John F.
Gaggar, Anuj
Lau, Audrey H.
Mo, Shuyuan
Suri, Vithika
Subramanian, Mani
Trinh, Huy N.
Tsang, Owen
Ryder, Stephen D.
Janssen, Harry L. A.
Chen, Chien Hung
HEPATOLOGY, 2019, 70 : 316A - 317A
[26] Safety and Efficacy of Switching to Tenofovir Alafenamide (TAF) in Virally Suppressed Chronic Hepatitis B (CHB) Patients With Renal Impairment: Week 48 Results From a Phase 2 Open-Label Study
Janssen, Harry
Heo, Jeong
Fournier, Claire
Ahn, Sang Hoon
Coffin, Carla S.
Hui, Aric Josun
Elkhashab, Magdy
Jafri, Syed-Mohammed
Mo, Shuyuan
Winans, Jake
Flaherty, John
Gaggar, Anuj
Chuang, Wan-Long
Gane, Ed J.
Lim, Young-Suk
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2021, 116 : S530 - S530
[27] EFFICACY AND SAFETY OF SWITCHING TO TENOFOVIR ALAFENAMIDE (TAF) IN VIRALLY SUPPRESSED CHRONIC HEPATITIS B (CHB) PATIENTS WITH RENAL IMPAIRMENT: WEEK 24 RESULTS FROM A PHASE 2 OPEN-LABEL STUDY
Janssen, Harry L. A.
Lim, Young-Suk
Gane, Edward J.
Fournier, Claire
Ahn, Sang Hoon
Tsang, Owen
Chuang, Wan Long
Heo, Jeong
Hui, Aric Josun
Elkhashab, Magdy
Chen, Chi-Yi
Su, Wei-Wen
Flaherty, John F.
Gaggar, Anuj
Tan, Susanna
Lau, Audrey H.
Suri, Vithika
Mo, Shuyuan
Subramanian, Mani
Jafri, Syed-Mohammed
Agarwal, Kosh
Lampertico, Pietro
Marchesini, Giulo
Coffin, Carla S.
Huang, Yi-Hsiang
HEPATOLOGY, 2019, 70 : 306A - 307A
[28] IMPROVEMENT IN VIROLOGIC, BIOCHEMICAL AND RENAL OUTCOMES IN CHRONIC HEPATITIS B (CHB) PATIENTS SWITCHED TO TENOFOVIR ALAFENAMIDE (TAF) IN ROUTINE CLINICAL PRACTICE
Yeh, Ming-Lun
Trinh, Sam
Huang, Chung-Feng
Hsieh, Ming-Yen
Huang, Ching-I
Liang, Po-Cheng
Huang, Jee-Fu
Dai, Chia-Yen
Chuang, Wan Long
Nguyen, Mindie H.
Yu, Ming-Lung
HEPATOLOGY, 2019, 70 : 295A - 296A
[29] COST-EFFECTIVENESS OF TENOFOVIR ALAFENAMIDE (TAF) FOR TREATMENT OF CHRONIC HEPATITIS B IN TAIWAN
Tan, E. C. H.
Yehoshua, A.
Jeyakumar, S.
Peng, P.
Lin, A. Y.
Smith, N.
Kachru, N.
VALUE IN HEALTH, 2022, 25 (12) : S145 - S145
[30] BONE AND RENAL SAFETY OF TENOFOVIR ALAFENAMIDE ( TAF) AT 8 YEARS IN CHRONIC HBV ( CHB) PATIENTS WITH UNDERLYING RISK FACTORS FOR USE OF TENOFOVIR DISOPROXIL FUMARATE ( TDF)
Buti, Maria
Gane, Edward J.
Agarwal, Kosh
Wong, Grace Lai-Hung C.
Lim, Young-Suk
Chen, Chi-Yi
Lim, Seng Gee
Yatsuhashi, Hiroshi
Fung, Scott K.
Abramov, Frida
Wang, Hongyuan
Yee, Leland J.
Flaherty, John F.
Pan, Calvin Q.
Marcellin, Patrick
HEPATOLOGY, 2023, 78 : S507 - S509

← 1 2 3 4 5 →